Fly News Breaks for September 9, 2015
Sep 9, 2015 | 08:52 EDT
As previously reported, BofA/Merrill downgraded Theravance to Underperform from Neutral. The firm downgraded shares following the SUMMIT COPD CV study failure and said expansion into the primary care market will be difficult without a label showing mortality benefit. BofA/Merrill lowered its price target to $13 from $16 on shares.
News For THRX From the Last 2 Days
There are no results for your query THRX